📰 Pooled Analysis News
Page 3 - Pooled Analysis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pooled Analysis. Real-time updates on events, politics, business and more.
August 11, 2023
This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.
June 8, 2023
A Total of 11 Poster Presentations Will Be Presented, Including Data from Two Pivotal Phase 3 Trials and 12-Month Safety Extension Trial of MIEBO™ ... | June 8, 2023
June 5, 2023
/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium...
June 4, 2023
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half ... | June 4, 2023
June 4, 2023
Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically
June 1, 2023
/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...
May 16, 2023
? Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder ? DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes
May 10, 2023
Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. , a... | May 10, 2023
May 10, 2023
Harmony Biosciences will present new efficacy data from a phase 2 study evaluating pitolisant in patients with Prader-Willi syndrome.
May 8, 2023
/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced the presentation of results from two clinical...